Acasti Pharma Inc. (NASDAQ:ACST) does about 3.27M shares in volume on a normal day but saw 55676404 shares change hands in Monday trading. The company now has a market cap of 23.71M USD. Its current market price is $0.24, marking a decrease of -65.49% compared to the previous close of $0.71. The 52 week high reached by this stock is $3.08 whilst the lowest price level in 52 weeks is $0.25. The script in recent trading has seen the stock touch a high of $0.2826 and a low of $0.2306.
Acasti Pharma Inc. (ACST) has a 20-day trading average at $0.7291 and the current price is -92.06% off the 52-week high compared with -2.12% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.6869 and its 200-day simple moving average is $0.9115. If we look at the stock’s price movements over the week, volatility stands at 11.39%, which decreases to 8.31% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 21.24 to suggest the stock is oversold.
5 analysts observing the Acasti Pharma Inc. (ACST) stock have set the 12-month price targets for the company’s shares at between $0.11 and $2.27. The median price target is 81.95% away from the current levels at $1.33.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 1 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 06, 2020 when B. Riley FBR upgraded the stock to “Buy” and issued a price target of $2. B. Riley FBR downgraded the stock to “Neutral” from Buy on January 13, 2020 at a price target of . B. Riley FBR initiated its price target at $7.75.
The current price level is -67.67%, -64.87%, and -73.42% away from its SMA20, SMA50, and SMA200 respectively, with the ACST price moving above the 50-day SMA on August 31. Acasti Pharma Inc. (ACST) stock is down -64.54% over the week and -67.80% over the past month. Its price is -90.01% year-to-date and -86.91% over the past year.
The stock last released its quarterly earnings report for quarter ended 11/29/2017, with the company’s earnings per share (EPS) of -$0.31 below consensus estimates by -$0.07. The company’s next earnings report is expected on 11/11/2020, with forecasts estimating quarterly EPS at -$0.16 and -$0.53 for whole year. ACST’s earnings per share are forecast to grow by 30.30% this year and 34.00% over next year.
Its 12-month price target is $1.33. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $0.11, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $2.27.
Outstanding shares total 96.89M with insiders holding 9.29% of the shares and institutional holders owning 6.09% of the company’s common stock. Price to book ratio is 2.06.
According to a U.S. Securities and Exchange Commission filing, Fidelity Nasdaq Composite Index F has reduced its position in Acasti Pharma Inc. (ACST) to 61,235 shares, mirroring a recent drop by 0.00%. Fidelity Nasdaq Composite Index F dumped 0.0 shares of Acasti Pharma Inc. common stock bringing its total worth to about $46539.0 at the end of recent close, SEC documents show. Series Portfolios Trust – Weiss A cut their holdings by -100.00% in the company over the course of the most recent quarter. It now holds a 0.00% position in Acasti Pharma Inc. thanks to 0.0 shares amounting to $0.0.